Page last updated: 2024-11-07

leukotriene b5

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

leukotriene B5 : A leukotriene composed of (6Z,8E,10E,14Z,17Z)-icosapentaenoic acid carrying (5S)- and (12R)-hydroxy substituents. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5283125
CHEBI ID88493
SCHEMBL ID10041226
MeSH IDM0119860

Synonyms (18)

Synonym
LMFA03020010
5s,12s-dihydroxy-6z,8e,14z,17z-eicosapentanenoic acid
leukotriene b5
ltb5
(5s,6z,8e,10e,12r,14z,17z)-5,12-dihydroxyicosa-6,8,10,14,17-pentaenoic acid
6,8,10,14,17-eicosapentaenoicacid, 5,12-dihydroxy-, (5s,6z,8e,10e,12r,14z,17z)-
SCHEMBL10041226
leukotrieneb5
(5s,6z,8e,10e,12r,14z)-5,12-dihydroxy-6,8,10,14,17-eicosapentaenoic acid
CHEBI:88493
5,12-dihepe
5,12-dihydroxy-6e-ltb5
5,12-dihydroxy-6-trans-leukotriene b(5)
(5s,6z,8e,10e,12r,14z)-5,12-dihydroxy-6,8,10,14,17-eicosapentaenoate
88763-92-2
Q27160373
DTXSID30868574
AKOS040755249

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Experiments examining the influence of Promega dosage indicated that the AA/EPA ratio in neutrophil lipids decreased in a dose-dependent manner."( Dietary n-3 fatty acid effects on neutrophil lipid composition and mediator production. Influence of duration and dosage.
Chilton, FH; Fonteh, AN; Hubbard, WC; Patel, M; Triggiani, M, 1993
)
0.29
" This study evaluated the effect of n-3 PUFA in a low, but recommended cardioprotective dosage on the formation of 5-lipoxygenase pathway metabolites in overweight subjects."( The effect of low-dose marine n-3 fatty acids on the biosynthesis of pro-inflammatory 5-lipoxygenase pathway metabolites in overweight subjects: a randomized controlled trial.
Aardestrup, I; Gammelmark, A; Madsen, T; Nielsen, MS; Obel, T; Schmidt, EB, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
rat metaboliteAny mammalian metabolite produced during a metabolic reaction in rat (Rattus norvegicus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
dihydroxy monocarboxylic acidAny hydroxy monocarboxylic acid carrying at least two hydroxy groups.
leukotrieneAny icosanoid from that family of C20 polyunsaturated fatty acids and their derivatives generated by leukocytes from arachidonic acid, each member having four double bonds of which three are conjugated.
long-chain fatty acidA fatty acid with a chain length ranging from C13 to C22.
hydroxy polyunsaturated fatty acidAny polyunsaturated fatty acid carrying one or more hydroxy substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (55)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (34.55)18.7374
1990's17 (30.91)18.2507
2000's11 (20.00)29.6817
2010's8 (14.55)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (19.30%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other46 (80.70%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]